Active Ingredient: Cetuximab
Cetuximab is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer in combination with encorafenib in patients who have received prior systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Intravenous, 400 milligrams cetuximab per square meter of body surface, one dose, over the duration of 1 week. Afterwards, intravenous, 250 milligrams cetuximab per square meter of body surface, once weekly.
Prior to the first infusion, patients must receive premedication with an antihistamine and a corticosteroid at least 1 hour prior to administration of cetuximab. This premedication is recommended prior to all subsequent infusions.
In patients with BRAF V600E mutant metastatic colorectal cancer, cetuximab is used in combination with encorafenib and FOLFOX or encorafenib. Evidence of BRAF V600E mutation status is required before initiating treatment with cetuximab. Mutational status should be assessed by a CE marked IVD with the corresponding intended purpose. If the CE-marked IVD is not available, an alternative validated test should be used.
In combination with encorafenib in patients who received prior systemic therapy:
Cetuximab is administered once a week. The very first dose is 400 mg cetuximab per m² body surface area (BSA). All subsequent weekly doses are 250 mg/m² each.
For the dosage or recommended dose modifications of concomitantly used encorafenib, refer to the product information for encorafenib. Encorafenib should be administered before starting cetuximab infusion.
It is recommended that cetuximab treatment be continued until progression of the underlying disease.
No dose adjustment is required in older people, but the experience is limited in patients 75 years of age and above.
Cetuximab is administered intravenously with an infusion pump, gravity drip or a syringe pump. The initial dose should be given slowly to minimize risk of infusion related reactions.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.